Melanoma: Accelerating cancer without mutations
For researchers, cutaneous melanoma is a conundrum. This deadly skin cancer arises from melanocytes, the cells that give our skin its color. It is tightly linked to sun exposure, yet the cancerous lesions often appear in places usually covered by clothes, and in people who are only intermittently in the sun. However, individuals who have experienced repeated sunburn, especially as a child, are more at risk. Overall, it is still unclear how these cancers emerge. Inherited genes – including those that guide skin pigmentation and DNA repair – explain a mere 18% of melanoma risk (Hulur et al., 2017).
It is difficult to study melanomas in humans in a controlled manner, so researchers have genetically engineered several strains of mice that can develop the disease (Day et al., 2017). Some of these strains get melanomas as adults after being exposed to a single dose of ultraviolet (UV) light early in life, resembling the way that adult humans are more likely to get skin cancers after multiple sunburn events as a child. Since UV light damages the DNA, it could potentially cause the genetic mutations that drive healthy cells to become cancerous, but studies have shown that this is rarely the case when mice receive a single early UV exposure (Mukhopadhyay et al., 2016). The UV dose could also create epigenetic changes – that is, modifications in how genes are expressed – but these do not force future mutations. So what is this single UV exposure doing?
Now, in eLife, Grant Morahan, Graeme Walker and colleagues – including Blake Ferguson as first author – report having pinpointed a small number of unexpected, normal genes that fast track the onset of either spontaneous or UV-induced melanomas (Figure 1; Ferguson et al., 2019). First, the researchers, who are based at the QIMR Berghofer Medical Research Institute, the Harry Perkins Institute of Medical Research and Edith Cowan University, selected a strain of mice genetically modified with two mutations found in human patients so the rodents can develop melanomas (including in response to an early UV dose). These animals were then crossed with 70 strains from a community resource, the Collaborative Cross. Mice from this resource have genetic backgrounds that contain a diverse collection of apparently normal variants of murine genes, often termed 'modifier genes' (Morahan et al., 2008). The offspring therefore all carried the two mutations that made them prone to melanomas, but each mouse also had different modifier genes inherited from its Collaborative Cross parent.
Spontaneous melanomas appeared more quickly in mice with variations in a DNA region that contained eight genes with mutations in their regulatory regions. One of these genes, Prkdc, emerged as a strong candidate because it carried two deleterious mutations. It codes for DNA-PK, an enzyme that repairs DNA double-strand breaks. Such breaks can arise if cells have difficulty replicating their genetic information before dividing. Failing to repair them leads to changes in the number of gene copies (which is often seen in cancer). Moreover, several genes with a similar DNA repair role are known tumor suppressors. In a human skin tissue bank, the researchers found that the expression of PRKDC was correlated with that of genes contributing to this repair mechanism. Curiously, its expression correlated even better with genes that participate in RNA-binding.
Melanomas that appeared after a single neonatal UV exposure were accelerated by changes in a specific DNA region on a different chromosome. These included missense mutations in Rrp15, the only gene in that region whose inheritance tracked the accelerated melanomas, and whose expression changed in the skin after UV exposure. The variants in Rrp15 did not impair DNA repair or enhance the migration of melanocytes or inflammatory cells, showing that they do not alter normal cellular responses in a way that could obviously lead to cancer. Unexpectedly, this gene codes for a protein present in ribosomes, which belongs to a family of RNA-binding proteins intimately involved in building these structures.
In fact, ribosomes have recently come under the spotlight as being more than workbenches for translating mRNA into protein. First, the specific RNA-binding proteins in a ribosome choose which mRNAs get translated into protein (Shi et al., 2017). In addition, RNA-binding proteins have signaling roles in the cell: deleting Rrp15 changes how the cell divides, kills itself or migrates into neighboring tissue (Xu et al., 2016; Dong et al., 2017). More broadly, disturbing the regulation of ribosomal proteins at the gene or protein level is associated with cells becoming cancerous, including in human melanomas (Xu et al., 2016; Hayward et al., 2017). Indeed, many proteins and pathways that are linked with cancer control the synthesis of ribosomal RNA, and are in turn regulated by ribosomal proteins (Quin et al., 2014; Xu et al., 2016).
These new roles add meaning to the observation that, in the context of spontaneous melanoma, the expression of PRKDC correlates with genes that code for RNA-binding proteins. Indeed, DNA-PK, the protein that PRKDC codes for, can also bind to RNA and has many other roles in the cell besides DNA repair. For instance, it intervenes on pathways linked to inflammation, skin differentiation, hormone responses, the control of the cell cycle, and the building of ribosomes. The prominent role of RNA-binding proteins in accelerating melanoma suggests we should reassess how they participate in early onset of cancer.
Based on this, Ferguson et al. draw two conclusions. Firstly, that somatic mutations – like the two present in the genetically engineered mice – were necessary but not sufficient for rapid cancers; the missing impetus came from normal germline variants in RNA-binding proteins. The number and diversity of such modifier genes means that any particular one may be found in only a few tumors, but when it comes to gene variants, frequency should not be confused with impact (Cannataro et al., 2018). Secondly, the team discovered that the formation of ribosomes was a major gene network upregulated by neonatal UV exposure. Therefore, they propose that global physiological events occurring hours after the single UV exposure are a step in cancer development that does not rely on somatic mutations. These physiological events evidently include a disturbance of ribosome composition that percolates into widespread changes in protein translation and stress responses. The similarity between the actors involved in early UV-induced and spontaneous melanomas is therefore not a coincidence, if, as the results suggest, neonatal UV exposure acts on seemingly healthy variants to cause physiological changes that also lead to problems in ribosome regulation.
In trying to learn how a single neonatal UV dose causes melanoma, Ferguson et al. went from the environment, to the genome, and back again. These results shine a light on physiological changes that cause, rather than result from, the emergence of cancer. Still, why do transient, cell-wide changes in every cell of the population precede rare, permanent mutations arising in a founder cell? A clue is that the cancer phenotype can arise from non-mutational changes. For instance, melanocytes can become cancerous within four weeks of UV exposure if certain growth factors are expressed in the surrounding skin (Berking et al., 2004). Perhaps we have the paradigm backward when picturing driver mutations as inexorably pushing cells into becoming cancerous. Instead, the environment may be creating reversible physiological changes that temporarily ratchet the cell toward cancer; ‘driver' mutations may then merely act as pawls, locking in these changes within an occasional cell that then cannot revert to its healthy state when the environmental stress has ended.
References
-
Effect sizes of somatic mutations in cancerJournal of the National Cancer Institute 110:1171–1177.https://doi.org/10.1093/jnci/djy168
-
Mouse models of UV-induced melanoma: genetics, pathology, and clinical relevanceLaboratory Investigation 97:698–705.https://doi.org/10.1038/labinvest.2016.155
-
Targeting the nucleolus for cancer interventionBiochimica et Biophysica Acta - Molecular Basis of Disease 1842:802–816.https://doi.org/10.1016/j.bbadis.2013.12.009
-
The role of ribosomal proteins in the regulation of cell proliferation, tumorigenesis, and genomic integrityScience China Life Sciences 59:656–672.https://doi.org/10.1007/s11427-016-0018-0
Article and author information
Author details
Publication history
Copyright
© 2019, Brash
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,032
- views
-
- 156
- downloads
-
- 1
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Cancer Biology
- Cell Biology
The canonical NF-κB transcription factor RELA is a master regulator of immune and stress responses and is upregulated in pancreatic ductal adenocardinoma (PDAC) tumours. In this study, we characterised previously unexplored endogenous RELA-GFP dynamics in PDAC cell lines through live single-cell imaging. Our observations revealed that TNFα stimulation induces rapid, sustained, and non-oscillatory nuclear translocation of RELA. Through Bayesian analysis of single-cell datasets with variation in nuclear RELA, we predicted that RELA heterogeneity in PDAC cell lines is dependent on F-actin dynamics. RNA-seq analysis identified distinct clusters of RELA-regulated gene expression in PDAC cells, including TNFα-induced RELA upregulation of the actin regulators NUAK2 and ARHGAP31. Further, siRNA-mediated depletion of ARHGAP31 and NUAK2 altered TNFα-stimulated nuclear RELA dynamics in PDAC cells, establishing a novel negative feedback loop that regulates RELA activation by TNFα. Additionally, we characterised the NF-κB pathway in PDAC cells, identifying how NF-κB/IκB proteins genetically and physically interact with RELA in the absence or presence of TNFα. Taken together, we provide computational and experimental support for interdependence between the F-actin network and the NF-κB pathway with RELA translocation dynamics in PDAC.
-
- Cancer Biology
In the realm of cancer immunotherapy, the meticulous selection of neoantigens plays a fundamental role in enhancing personalized treatments. Traditionally, this selection process has heavily relied on predicting the binding of peptides to human leukocyte antigens (pHLA). Nevertheless, this approach often overlooks the dynamic interaction between tumor cells and the immune system. In response to this limitation, we have developed an innovative prediction algorithm rooted in machine learning, integrating T cell receptor β chain (TCRβ) profiling data from colorectal cancer (CRC) patients for a more precise neoantigen prioritization. TCRβ sequencing was conducted to profile the TCR repertoire of tumor-infiltrating lymphocytes (TILs) from 28 CRC patients. The data unveiled both intra-tumor and inter-patient heterogeneity in the TCRβ repertoires of CRC patients, likely resulting from the stochastic utilization of V and J segments in response to neoantigens. Our novel combined model integrates pHLA binding information with pHLA-TCR binding to prioritize neoantigens, resulting in heightened specificity and sensitivity compared to models using individual features alone. The efficacy of our proposed model was corroborated through ELISpot assays on long peptides, performed on four CRC patients. These assays demonstrated that neoantigen candidates prioritized by our combined model outperformed predictions made by the established tool NetMHCpan. This comprehensive assessment underscores the significance of integrating pHLA binding with pHLA-TCR binding analysis for more effective immunotherapeutic strategies.